Intercytex. (Hairmultiplication)

[INT]

Oorspronkelijk geplaatst door Gideon

Ze plaatsen DHT vrije haren, zoals de haren die achter op je hoofd zitten (daarom houden kale mensen altijd een kransje over van de haren die niet uitvallen).

BTW kan iemand me hier even mee helpen? Ik snap het verschil nog steeds niet echt of komt het op hetzelfde neer.

Moet je hier nu ook al flink kaal voor zijn ofniet?

[Vince001]

Voor de liefhebber, intercytex heeft wat info over hun phase II op hun site geplaatst:

The Phase II trial of ICX-TRC, their cell therapy product for hair regeneration in male-pattern baldness, began in September 2006. The process involves taking a biopsy from the subject, separating out the relevant cells, and growing them in their facility using a proprietary process.

All biopsies from the first group of 9 patients have been taken and most of these patients have been treated. Further groups will follow to investigate variations in the delivery technique. Intercytex expect to report preliminary data from this trial around the middle of 2007.

In the Phase I trial, which had 7 subjects, there were no safety issues and 5 out of the 7 patients had an increased number of hairs after treatment. The Phase II trials have 10 patients per group and is ongoing. It is an efficacy trial designed to look for new hair growth.

Intercytex has also received a £1.8m grant from the British government to assist in the commercialization of their process.

[Tommie01]

“We are investigating whether there are opportunities to initiate the small scale commercialisation of
ICX-TRC in 2008. This will depend on the outcome of the ongoing Phase II trial and further regulatory review.”
Bron: http://www.intercytex.com/icx/news/releases/2007/2007-03-23/2007-03-23.pdf

Het bepalen van de waarde die hieraan gehecht dient te worden, laat ik aan eenieder zelf over.

[Tibetaan]

http://news.hairlosshelp.com/hair-cl...ing-procedure/

2010 op de markt.

FAQ's zien er veelbelovend uit! Dus nog maar even geen HT dus

[Jaapie]

Follicular Cell Implantation: An Emerging Cell Therapy for Hair Loss by Jeff’ Teumer PhD and Jerry Cooley MD, Seminars in Plastic Surgery/Volume 19, Number 2, 2005
http://www.thieme-connect.com/ejourn.../s-2005-871735



Heeft er iemand hier toegang tot het members-gedeelte? Ik ben wel benieuwd naar de full-text article.

[Jaapie]

Nieuwe press release van intercytex, 25 September 2007.

Voor de volledige press release in PDF formaat, klik hier
Intercytex Group plc – Interim results for the six months ended 30 June 2007


25th September 2007

Positive efficacy data emerging across regenerative medicine product portfolio

Intercytex Group plc (LSE: ICX), the regenerative medicine company developing innovative products to restore skin and hair, announces its interim results for the six months ended 30 June 2007.
Intercytex is a healthcare company developing regenerative medicine products for the woundcare and aesthetic medicine markets. It uses its expertise in cell therapy technology to develop innovative products that harness the innate ability of human cells to regenerate and repair the body.
Highlights
Products

• Skin grafts – clinical breakthrough in regenerative medicine announced in June with positive results from ICX-SKN Phase I trial for skin grafts in acute wounds
• Facial rejuvenation – Phase II trial of VAVELTA® underway; low dose treatments completed. VAVELTA introduced to UK market at FACE exhibition in London
• Hair regeneration – first 12 patients treated in Phase II trial of ICX-TRC
• Chronic wounds – safety review board (DSMB) recommends continuation of ICX-PRO Phase III trial and increase sample size, based on a review of data from the first 108 patients

Corporate

• Placing of new shares in May raised £12m gross
• Comprehensive supply agreement signed with Baxter Healthcare for use of Tisseel® in ICX-PRO and ICX-SKN

Financial

• Loss before tax for the six months ended 30 June 2007 of £6.04m (H1 2006: £4.04m)
• Cash and cash equivalents and liquid investments at 30 June 2007 of £17.55m (H1 2006: £15.10m)
• Milestone payment of US$200,000 received from Bosley under ICX-TRC option

Post period-end highlights

• Preliminary data from Phase II trial of VAVELTA in facial rejuvenation shows very encouraging efficacy data and a good safety profile. Treatment of high dose group commenced
• Commencement of second VAVELTA trial in acne scars
• Preliminary data from Phase II trial of ICX-TRC for hair regeneration shows increased hair counts and good safety profile
• Recruitment completed for Phase II trial of ICX-PRO for diabetic foot ulcers

Nick Higgins, CEO commented: "We announced a clinical breakthrough in regenerative medicine in June with the release of data from our skin repair trial and we are now seeing this success being repeated across our portfolio. Positive efficacy data is being generated on all of our regenerative medicine products, giving us great optimism for their commercial potential. With the additional funding we now have in place, Intercytex is in a very strong position to exploit the opportunities in the rapidly growing field of regenerative medicine."
There will be an analyst meeting to discuss the interim results today at 11am at Financial Dynamics. For those unable to attend, there will be a live audio conference call, the details are as follows. This is a listen only number:
Dial in time: 11am
Dial in number: 020 7806 1966
Title: Intercytex
Slides: http://www.intercytex.com/icx/invest...2007-09-25.pdf
If you would like to participate in the question and answer session at the end of the call, please call Claire Rowell on 0207 269 7285 to get the relevant dial in number as it differs from the one above.
Enquiries
For more information, contact:
Intercytex Group plc
Nick Higgins, Chief Executive Tel: 0161 904 4500 Richard Moulson, Chief Financial Officer Tel: 0161 904 4500 Financial Dynamics David Yates Tel: 0207 269 7156 Piper Jaffray David Rasouly Tel: 0203 142 8739 Notes for Editors
Intercytex is a healthcare company developing regenerative medicine products for the woundcare and aesthetic medicine markets. It uses its expertise in cell therapy technology to develop innovative products that harness the innate ability of human cells to regenerate and repair the body. Intercytex has 4 products in development:

• ICX-PRO, designed to stimulate active repair in chronic wounds – in a Phase III trial
• ICX-SKN, being developed as a durable and robust skin replacement – recently completed a Phase I trial
• VAVELTA® (ICX-RHY), a facial rejuvenation product already introduced to the UK market.
• ICX-TRC, a hair regeneration product – in a Phase II trial

All Intercytex' products are derived from unmodified human cells.
Intercytex commenced operations in 2000 and currently employs around 75 staff. In addition to its head office in Cambridge, UK, it has a GMP clinical production facility with research and development laboratories in Manchester, UK. Additional laboratories are located in Boston, USA.
Intercytex' shares trade on AIM, a market of the London Stock Exchange, under the ticker symbol ICX.L.
Additional information on the Company can be found at www.intercytex.com
Statements contained within this press release may contain forward-looking information or statements with respect to the financial condition, results of operations and business achievements/performance of Intercytex and certain of the plans and objectives of management of Intercytex with respect thereto. By their nature, forward-looking statements involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or similar expressions. A number of factors, including the satisfactory progress of research and development, could cause Intercytex' actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements. Forward projections reflect management's best estimates based on information available at the time of issue and are not a guarantee of future performance. Other than as required by applicable law, Intercytex does not undertake any obligation to update or revise any forward-looking information or statements to reflect events or circumstances after the date of this release. The term "Intercytex" refers to Intercytex Group plc and its subsidiary undertakings.
View the full press release in PDF format (PDF, 124 KB, opens in a new window).



------------------------

Hair regeneration - ICX-TRC
ICX-TRC consists of a suspension of autologous dermal papilla (DP) cells. These cells are able to
stimulate the generation of new hairs when injected into the scalp in close proximity to the epithelial
cells which generate the hair. The purpose of the ongoing Phase II study being conducted by Dr
Bessam Farjo in Manchester is to optimise the delivery of the DP cells.
In this study, hair counts are obtained by shaving and photographing a small section of scalp,
injecting it and then applying a specialised image analysis system to provide a total hair count. Two
sub-groups were each injected with autologous DP cells using different delivery techniques. The
first group focussed on delivery of the hair inductive DP cells, and in the second group resident hair
producing (epithelial) cells were also stimulated at the time of delivery.
Although it is too early to determine fully the differences between the sub-groups, the preliminary
data are encouraging. In the first sub-group 2 patients out of 5 showed substantial increases in hair
count (21 & 55%) at 24 weeks. In the second sub-group (5 patients in total) injected more recently,
all patients showed substantial and visible increased hair counts at 6 and/or 12 weeks (13-105%).
We believe this increased hair production is attributable to the interaction between the injected DP
cells and the stimulated resident hair producing cells.
A further 8 subjects will be treated with variations in delivery technique. The full data set on all
subjects at 24 weeks will be available in the middle of 2008. This detailed analysis will form the
basis of further Phase II or Phase III trials as appropriate.
At the end of the trial photographic data will be analysed from a much larger area of treated scalp
on all subjects at 12 months. Currently 2 patients have been lost to follow up.

[michelangelo]

Wauw!!! Dat is heel goed nieuws!
Ik heb nog nooit ergens gelezen dat een haircount met 105% is toegenomen binnen 12 weken!! Tevens werkt het ook bij alle proefpersonen, maar niet bij iedereen even goed.

Ik vraag me wel af in hoeverre de haren blijven groeien na de behandeling... Zou je ieder half jaar een nieuwe injectie moeten krijgen?

Ik kan niet wachten tot dit op de markt komt, vanaf nu ga ik sparen.

Misschien is een kleine investering in Intercytex aandelen geen verkeerd idee.

[Henk]

Hé bedankt Jaapie.
Ja, dat lijkt heel goed nieuws.

[Ryan R]

Jezus jongens, ik krijg ineens weer echt volle hoop op het idee dat ik mn hele leven gewoon met een kop met een goeie bos haar kan rondlopen .

[lexx]

Zolang de behandeling nog niet beschikbaar of in ieder geval officieel aangekondigd is moet ik het nog zien, maar inderdaad, het ziet er bijzonder veelbelovend uit! Benieuwd of ze nog proefpersonen zoeken...

[Morehair]

Tja, Intercytex moet toch wat doen om de geldschieters tevreden te houden.......

[Jaapie]

Oorspronkelijk geplaatst door Morehair

Tja, Intercytex moet toch wat doen om de geldschieters tevreden te houden.......

pessimist. Luister naar profeet Jaapie, ICX-TRC zal binnen 3 jaar op de markt gebracht worden.

[frank@]

laten we het hopen............die 3 jaar houd men haardos het nog wel uit!!!

[lexx]

That's the spirit Jaapie!

[Morehair]

Oorspronkelijk geplaatst door Jaapie

pessimist. Luister naar profeet Jaapie, ICX-TRC zal binnen 3 jaar op de markt gebracht worden.

Een realist is niet altijd een pessimist.